La pregunta, en términos claros
Roughly three-quarters of babies born with sickle cell disease each year are born in sub-Saharan Africa. The approved CRISPR treatment costs over two million dollars and requires a hospital with a transplant unit, cell manufacturing and weeks of intensive care. The gap between where the disease is and where the treatment can be delivered is not a detail — it is the central fact about gene-editing medicine today.
Approved gene-editing therapy costs $2.2 million per patient at list price and requires apheresis, GMP cell manufacturing, myeloablative conditioning and transplant-capable inpatient care. Sickle cell disease burden is concentrated in sub-Saharan Africa and India, where such infrastructure is largely absent. Proposed responses include in vivo approaches that avoid cell manufacturing and conditioning, regional manufacturing capacity, tiered pricing, outcomes-based payment and public or philanthropic development — none yet demonstrated at scale.
The arguments
- High prices fund the development that produced the therapy, and no therapy is worse than an expensive one.
- Prices fall as manufacturing matures and competition arrives; first-generation costs are not permanent.
- One-time treatments may cost less over a lifetime than decades of transfusions, hospital admissions and lost productivity.
- Public and philanthropic programmes are already funding work explicitly aimed at affordable versions.
- Pricing at what health systems will bear rather than what treatment costs makes universal access structurally impossible.
- Public funding underwrote much of the foundational science, so the public has already paid once.
- Development priorities follow purchasing power, which is why programmes cluster in wealthy-market indications.
- A treatment that exists but cannot reach the people who need it raises expectations without meeting them, which has its own harm.
Where the science actually stands
The affordability and delivery problem is acknowledged across the field, including by the companies involved and by the scientists who developed the technology. What is contested is the remedy: market maturation, public investment, in vivo simplification, or structural change in how such medicines are priced and paid for.
Unresolved questions
- Whether in vivo editing can remove enough cost and infrastructure to change the picture.
- Whether regional manufacturing in affected countries is achievable.
- How health systems should pay for treatments whose benefits accrue over decades to a different payer.
- Whether public funding of foundational science should carry pricing obligations.
Sources
- World Health Organization
Sickle cell disease ↗